Pharma

By Dave Muoio December 5, 2018
Digital pharmacy Alto today announced the closure of its $50 million Series C funding round. The investment was led by Zola Global and Greenoaks Capital, with additional participation from Jackson Square Ventures, Olive Tree Capital and other unnamed investors. According to the company, the latest funding will help the company push its tech-driven prescription delivery service to new regions...
By Jonah Comstock December 3, 2018
The FDA has announced the winners of the opioid addiction innovation challenge the agency launched last May. Out of more than 250 applications from medical device developers, the FDA selected eight winners.  "While these products will not automatically receive marketing authorization from the FDA, the device developers will receive increased interaction with CDRH experts, guidance for clinical...
By Jack Kaufman November 30, 2018
About the Author: Jack is a marketing and community associate at Dreamit, where he focuses on sourcing and evaluating health tech startups and creating opportunities for Dreamit to engage with the startup ecosystem in New York City and beyond. Before joining Dreamit, Jack worked as an associate at Bombas, a mission-driven, high-end apparel startup. He graduated cum laude from Haverford College...

Novartis' recently-opened digital health innovation lab in San Francisco. Photo courtesy Novartis on Twitter.

By Jonah Comstock November 21, 2018
Last month, Novartis announced that it would be cutting 2,200 jobs as part of a restructuring of the company focusing on particular priorities. “The overall strategy we have is to focus the company as a leading medicines company powered by digital technologies,” CEO Vas Narasimhan told STAT News last month. “What that has meant is to exit certain health care sectors or segments … — so we exited...
By Dave Muoio November 20, 2018
reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April. But while physical prescription drugs are usually handled through a pharmacy, the process...
NovioSense's artist conception of its device in use.

NovioSense's artist conception of its device in use.

By Jonah Comstock November 20, 2018
Last week, Alphabet subsidiary Verily Life Sciences announced the end, at least for the foreseeable future, of its glucose-sensing contact lens collaboration with Novartis. Verily CTO Brian Otis gave his thoughts in a blog post at the time, stressing the learnings the company got from the project. In a recent interview with MobiHealthNews, Novartis Global Head of Digital Development Jacob LaPorte...
By Dave Muoio November 19, 2018
The FDA is seeking public comments for a proposed framework that would allow the majority of apps and software released by pharmas that accompany a drug treatment to avoid lengthy premarket review submissions. According to a notice released last week, such software would be viewed as “promotional labeling,” and therefore only require submission to the FDA’s Office of Prescription Drug Promotion (...
By Jonah Comstock November 16, 2018
Four years after announcing an ambitious — and often ridiculed — project to create a glucose-sensing contact lens along with Novartis subsidiary Alcon, Alphabet's Verily is throwing in the towel, the company announced in a blog post today. It will continue to work on two other medical contact lens projects, aimed at presbyopia and cataract surgery recovery. "Our clinical work on the glucose-...
By Jonah Comstock November 15, 2018
Belgian biopharma company UCB has tapped customer engagement company Verint Systems to create an app for patients with Parkinson's disease. The app is called PD Coach and includes an AI assistant named April which can communicate with users either by text or speech. At launch, the app will support journaling and symptoms tracking. April is programmed with a wealth of Parkinson's-specific...